Martin Dietrich, MD, PhD, discusses ways of offsetting neratinib-associated diarrhea for patients with early-stage HER2-positive breast cancer at high risk of recurrence in need of extended adjuvant therapy.
Original Article: Antidiarrheal Prophylaxis Optimizes Neratinib Use in HER2+ Breast Cancer